From the link:
Total number of enrollees: 5,050
The primary outcome, cardiovascular death or hospitalization for heart failure, occurred in 35.5% of the vericiguat group compared with 38.5% of the placebo group (hazard ratio [HR] 0.90, p = 0.019).
I would consider it a very poor outcome if MSB's improvement were as slim as this. Pretty hard to charge the kind of money we all dream about (pun intended) for that level of improvement.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.52 |
Change
-0.060(2.33%) |
Mkt cap ! $3.225B | |||
| Open | High | Low | Value | Volume |
| $2.58 | $2.61 | $2.50 | $12.63M | 4.955M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8366 | $2.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.53 | 8780 | 4 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |